NASDAQ:FEMY Femasys 8/8/2024 Earnings Report $0.95 +0.03 (+3.26%) As of 01:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Femasys EPS ResultsActual EPS-$0.21Consensus EPS -$0.18Beat/MissMissed by -$0.03One Year Ago EPSN/AFemasys Revenue ResultsActual Revenue$0.22 millionExpected Revenue$0.50 millionBeat/MissMissed by -$280.00 thousandYoY Revenue GrowthN/AFemasys Announcement DetailsQuarterDate8/8/2024TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsFemasys' next earnings date is estimated for Thursday, August 14, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Femasys Earnings HeadlinesFemasys Enters Purchase Agreement with Alumni CapitalJuly 3, 2025 | tipranks.comFemasys Gains Regulatory Approvals in Australia and New ZealandJuly 1, 2025 | tipranks.comBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change. July 9 at 2:00 AM | Crypto 101 Media (Ad)Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue DiagnosticJuly 1, 2025 | globenewswire.comFemasys Inc. Receives CE Mark Certification for Revolutionary FemBloc® System for Non-Surgical Permanent Birth Control - NasdaqJune 27, 2025 | nasdaq.comFemasys Gains European Approval for FemBloc SystemJune 26, 2025 | msn.comSee More Femasys Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email. Email Address About FemasysFemasys (NASDAQ:FEMY), Inc. is a medical device company dedicated to the design, development and commercialization of minimally invasive diagnostic and therapeutic products for women’s reproductive health. Headquartered in Irvine, California, the company is listed on the NASDAQ under the ticker FEMY and focuses on single‐use catheter technologies that enhance procedure accuracy and patient comfort in fertility care. Its flagship offerings include the FemVue™ catheter system for non‐radiation fallopian tube patency assessment and the FEMME™ embryo transfer catheter, both engineered with proprietary designs and radiopaque markers. These devices address key challenges in assisted reproductive technology by streamlining workflows, reducing patient discomfort and improving clinical outcomes in infertility clinics and hospitals. Founded in 2012, Femasys serves markets across North America, Europe, Asia-Pacific and select emerging regions. The company has secured CE Mark approval in Europe and is actively pursuing regulatory clearances in the United States and China. Femasys leverages a combination of direct sales and distributor partnerships to expand its global footprint in the rapidly growing fertility device market. Under the guidance of an experienced executive team, Femasys is advancing a pipeline of next‐generation catheter systems for enhanced uterine and tubal imaging. The company’s board of directors brings deep expertise in healthcare innovation, regulatory strategy and commercial expansion, positioning Femasys to broaden its product portfolio and scale operations worldwide.Written by Jeffrey Neal JohnsonView Femasys ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings Bank of America (7/14/2025)America Movil (7/15/2025)Wells Fargo & Company (7/15/2025)Citigroup (7/15/2025)Charles Schwab (7/15/2025)Bank of New York Mellon (7/15/2025)Progressive (7/15/2025)JPMorgan Chase & Co. (7/15/2025)UnitedHealth Group (7/15/2025)BlackRock (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
